Cancer Aware · Patient & Family Guide

Frequently Asked Questions and Patient Decision Guide

Use these answers to prepare for a conversation with your team. They explain common concerns but cannot replace review of your own reports and circumstances.

Educational information for patients and families. This guide supports, but does not replace, individualized medical advice. It cannot diagnose, stage cancer or prescribe treatment.

All 25 chapters

Chapter 25 of 25

Understanding the diagnosis

1. Is endometrial cancer curable?

Many early-stage cancers are treated with curative intent. The likelihood of long-term control depends on the complete stage, pathology, molecular findings and treatment, not the name alone.

2. Does postmenopausal bleeding always mean cancer?

No. Benign causes are common, but even one episode should be assessed promptly so that important causes are not missed.

3. Can it occur before menopause?

Yes. Persistent abnormal bleeding in younger people may need sampling, especially with relevant risk factors or failed initial treatment.

4. Can a normal Pap test exclude it?

No. Cervical screening does not adequately assess the uterine lining. Bleeding needs its own diagnostic pathway.

5. Is a thin lining on ultrasound always reassuring?

It can be informative in context, but does not universally exclude cancer. Current ACOG guidance recommends ultrasound and tissue sampling for most postmenopausal bleeding; persistent symptoms require reassessment.

6. Is an inadequate biopsy a negative result?

No. It means there was not enough interpretable tissue to answer the question. Ask whether repeat sampling or hysteroscopy is needed.

7. Is endometrial cancer contagious?

No. It cannot be passed to a partner or family member through ordinary contact or sexual activity.

8. Is it caused by HPV?

Most endometrial cancers are not HPV-driven. HPV prevention remains important for cervical and other cancers, but is a separate topic.

Reports, biomarkers and inheritance

9. Is grade the same as stage?

No. Grade describes microscopic appearance; stage describes a classification of extent and, in FIGO 2023, selected biological features.

10. What does MMR deficiency mean?

The tumour has impaired DNA mismatch repair. This may influence immunotherapy choices and trigger assessment for Lynch syndrome.

11. Does MMRd mean I have Lynch syndrome?

Not necessarily. Many cases are acquired. Methylation and germline testing help distinguish inherited from noninherited causes.

12. Does a POLE mutation mean a better prognosis?

A qualifying pathogenic proofreading-region mutation often indicates favourable early-stage biology. An uncertain variant or advanced-stage context must not be interpreted the same way.

13. What does p53-abnormal mean?

It describes a tumour biological group often associated with higher risk. It does not automatically diagnose an inherited TP53 condition.

14. Does NSMP mean no cancer mutations exist?

No. It means the tumour does not fit the other three classifiers after appropriate testing. Grade and ER help refine its risk.

15. Can more than one molecular test be abnormal?

Yes. Multiple-classifier cancers need expert interpretation; qualifying POLE and MMRd findings generally take precedence over secondary p53 abnormalities.

16. Should relatives have genetic testing?

A confirmed inherited pathogenic variant may justify counselling and targeted family testing. A tumour result or uncertain variant alone is not enough to make that decision.

Choosing treatment

17. Is hysterectomy always necessary?

It is standard for many localized cancers, but selected fertility-preserving or medically inoperable situations have alternatives under specialist care.

18. Can pregnancy be possible after diagnosis?

Selected grade-1 endometrioid cancers without invasion or spread may be managed conservatively. Pregnancy planning follows documented response and specialist review; success is not guaranteed.

19. Can ovaries be preserved?

Sometimes, in carefully selected premenopausal low-risk patients. Genetic risk, disease features and ovarian findings matter; keeping ovaries does not preserve the uterus after hysterectomy.

20. Is chemotherapy necessary after surgery?

Not for everyone. Many low-risk patients need observation only, while higher-risk features may justify chemotherapy, radiation or both.

21. Why might no additional treatment be recommended?

If recurrence risk is low and added treatment offers little benefit, avoiding toxicity is an evidence-based choice. Follow-up remains important.

22. Is vaginal brachytherapy the same as pelvic radiation?

No. Brachytherapy focuses near the vaginal cuff; external-beam treatment can cover a wider pelvic area. Their benefits and side effects differ.

23. Will I be radioactive after brachytherapy?

After usual temporary high-dose-rate treatment, the source is removed and you do not remain radioactive. Confirm the technique and instructions with the centre.

24. When is immunotherapy recommended?

It is important in eligible advanced or recurrent disease, with biomarker and regimen-specific indications. It is not routine for every early-stage MMRd cancer.

25. Do I need a positive PD-L1 test for these treatments?

PD-L1 CPS is not generally required for the principal endometrial chemo-immunotherapy or lenvatinib–pembrolizumab indications. The exact label and clinical setting still matter.

26. Are pembrolizumab and dostarlimab interchangeable after resistance?

Switching from one PD-1 antibody to another is not a proven general strategy after progression. Previous treatment and trial options need review.

27. Is hormonal therapy only for fertility preservation?

No. It can also control selected receptor-positive, low-grade, slowly progressing advanced or recurrent cancers.

28. Is HER2 treatment suitable for every endometrial cancer?

No. The tumour must meet the relevant biomarker and disease-setting criteria. Different medicines have different thresholds and regional approvals.

Recovery and living well

29. Can cancer return after hysterectomy?

Yes, because microscopic cells may remain or have spread before surgery. Risk varies, which is why postoperative assessment and follow-up matter.

30. Should I have PET-CT at every follow-up?

Usually not. Imaging should answer a clinical question or follow an individualized high-risk plan, rather than be automatic at every visit.

31. Does a normal CA-125 rule out recurrence?

No. It is not informative for every cancer and should not override symptoms or examination findings.

32. Can treatment affect sexual health?

Yes. Dryness, narrowing, pain, menopause and body-image changes can occur. Ask about lubricants, rehabilitation, symptom treatment and counselling.

33. Can diet cure the cancer?

No diet or supplement is proven to replace effective treatment. Adequate nutrition supports recovery; restrictive diets can cause harm.

34. When should I call urgently during treatment?

Fever during chemotherapy, severe illness, new breathlessness, heavy bleeding, severe diarrhoea or concerning immune symptoms require prompt contact or emergency care.

35. Does palliative care mean giving up?

No. It supports symptom relief and quality of life alongside active anticancer treatment, as well as when comfort becomes the main goal.

36. What should I ask before joining a trial?

Ask about the study purpose, standard alternatives, randomization, known risks, extra visits, costs and what happens if treatment is stopped.

Your practical consultation checklist

  • Confirm the exact histology, grade, FIGO version and stage.
  • Ask which molecular tests are complete and whether genetics referral is needed.
  • Clarify treatment intent, expected benefits, alternatives and lasting effects.
  • Discuss fertility, menopause, sexual health, work, travel and costs.
  • Obtain a written symptom action plan and emergency contact.
  • Confirm the next appointment, pending results and who will communicate them.

Related chapters

References and review status

Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.

Evidence scope and update policy